论文部分内容阅读
目的：探讨多药耐药（ＭＤＲ）Ｐ糖蛋白（Ｐ１７０）表达与急性白血病预后关系。方法：采用抗Ｐ１７０单克隆抗体ＪＳＢ－１及碱性磷酸酶抗碱性磷酸酶免疫细胞化学技术检测８６例（１０４例次）急性白血病骨髓细胞Ｐ１７０表达。结果：Ｐ１７０阳性率难治组为７６．９％（１０／１３），复发组４０．９％（９／２２），初治组２７％（１０／３７），完全缓解组１８．８％（６／３２）。初治组Ｐ１７０阴性病例首次诱导完全缓解（ＣＲ１）率８１．５％，Ｐ１７０阳性ＣＲ１率４０％（Ｐ＜０．０５）。复发组Ｐ１７０阴性患者再诱导化疗完全缓解（ＣＲ２）率３０．８％（４／１３），Ｐ１７０阳性患者ＣＲ２率１１．１％（１／９）。结论：Ｐ１７０表达与急性白血病缓解、复发及耐药有关。Ｐ１７０检测有助于判断急性白血病疗效及预后，并为临床选择应用逆转剂治疗耐药病例提供依据
Objective: To investigate the relationship between the expression of multidrug resistance (MDR) P glycoprotein (P170) and the prognosis of acute leukemia. METHODS: The expression of P170 in 86 cases (104 cases) of acute leukemia bone marrow cells was detected by anti-P170 monoclonal antibody JSB-1 and alkaline phosphatase anti-alkaline phosphatase immunocytochemistry. Results: The P170-positive rate was 76.9% (10/13) in the refractory group, 40.9% (9/22) in the relapse group, 27% (10/37) in the untreated group, and 18.8% in the complete remission group (P<0.05). 6/32). The rate of complete remission (CR1) was 81.5% and the rate of P170 positive CR1 was 40% (P<0.05) in the P170-negative cases of the untreated group. The rate of complete remission (CR2) for re-induction chemotherapy (CR2) was 30.8% (4/13) in patients with relapse of P170, and 11.1% (1/9) for P170-positive patients. Conclusion: The expression of P170 is related to the remission, relapse and drug resistance of acute leukemia. The P170 test is helpful in judging the curative effect and prognosis of acute leukemia, and provides a basis for the clinical application of reversal agents to treat drug-resistant cases.